SOUTH SAN FRANCISCO, Calif., Sept. 9, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that the pre-specified response criteria to proceed to full enrollment of 56 patients has been achieved in its pivotal clinical trial of Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)) for the treatment of adult acute lymphoblastic leukemia (ALL) in second relapse.
